ClinicalTrials.gg
CompletedNCT00298038Updated Sep 18, 2019Results posted

A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

A Phase 3 interventional study of Rifaximin and Placebo in Hepatic Encephalopathy, sponsored by Bausch Health Americas, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
299
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.

Enrollment
3rd of 18
299 · median 94
Started
2005
with 1 other
Phase 3
4 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
4 of 18
Bausch Health Americas, Inc.

Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one is the 3rd largest by enrollment, is one of 2 that started in 2005, is one of 4 in phase 3, and was the 2nd registered.

Hepatic Encephalopathy

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

Browse Hepatic Encephalopathy studies →

Open to participants now

3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rifaximin in Hepatic Encephalopathy, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).

03

Conditions studied

  • Hepatic Encephalopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must sign an Form
  • In remission from past HE
  • Uses appropriate measures
  • More than or equal to 18 years of age
  • Must have potential to benefit from treatment
  • Recent prior HE episodes
  • Capable and willing to comply with all study procedures
  • Participant has personal support available
  • Has a certain Model End Stage Liver Disease (MELD) score
  • Recent transjugular intrahepatic portosystemic shunt (TIPS) placement or revision

Exclusion criteria

Exclusion Criteria:

  • Significant medical conditions, medical conditions that may impact study participation, or Investigator decision not to include
  • Allergies to the study drug or similar drugs
  • Laboratory abnormalities
  • Recent participation in another clinical trial
  • History of non-compliance
  • Pregnant or at risk of pregnancy, or is lactating
  • Recent alcohol consumption
  • Active bacterial or viral Infections
  • Bowel issues
  • Active
  • On a prohibited medication
  • Liver transplant expected in near term
  • Lactulose intolerance
  • Participant shows presence of intestinal obstruction or has inflammatory bowel disease
  • Ongoing or recent GI bleed
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
299 participants (actual)

Study arms

  • Experimental
    Rifaximin

    Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.

    Drug: Rifaximin

  • Placebo comparator
    Placebo

    Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.

    Drug: Placebo

Interventions

  • Oral

    Also known as: Xifaxan®

  • DrugPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. Time To The First Breakthrough Overt HE Episode

    Time to a breakthrough overt HE episode was the duration (number of days) from time of first dose of study drug to the first breakthrough overt HE episode. A breakthrough overt HE episode was defined as an increase of Conn score from Grade 0 or 1 to ≥2, or an increase in Conn and asterixis score of 1 grade each for those participants who entered the study with a Conn score of 0. Participants who completed the study and did not experience a breakthrough overt HE episode were censored at the time of their 6-month visit. Participants who terminated early for reasons other than a breakthrough overt HE episode were contacted at 6 months from randomization to determine if they had experienced a breakthrough overt HE event or other outcome. Participants without breakthrough overt HE were censored at the time of last contact or death, whichever was earlier. The number of events of a first breakthrough overt HE episode during the treatment interval is presented.

    Time frame: Baseline up to 6 Months (168 days)

Secondary outcomes

  1. Time To First HE-related Hospitalization

    Time to first HE-related hospitalization is defined as the duration (number of days) between the first dose of study drug and the date of first HE-related hospitalization. Participants who discontinued prior to hospitalization due to HE and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of participants with their first HE-related hospitalization per interval is presented. The number of events of the first HE-related hospitalization during the treatment interval is presented.

    Time frame: Baseline up to 6 months

  2. Time To Any Increase From Baseline In Conn Score

    Time to any increase in Conn score (mental state grade) was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in Conn score. Conn score range: Grade 0 (no behavioral abnormality) to Grade 4 (coma; unable to test mental state). Participants who discontinued prior to experiencing an increase in Conn score and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in Conn score during the treatment interval is presented.

    Time frame: Baseline up to 6 months

  3. Time To Any Increase From Baseline In Asterixis Grade

    Time to any increase in asterixis grade was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in asterixis grade. Asterixis (flapping tremor) was determined with the participant holding both arms and forearms extended with wrists dorsiflexed and fingers open for ≥30 seconds per standard practice. Asterixis grade range: Grade 0 (no abnormal movement) to Grade 4 (almost continuous flapping motions). Participants who discontinued prior to experiencing an increase in asterixis grade and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in asterixis grade during the treatment interval is presented.

    Time frame: Baseline up to 6 months

  4. Mean Change From Baseline In Fatigue Domain Score On The CLDQ At End Of Treatment

    The 29-item Chronic Liver Disease Questionnaire (CLDQ) questionnaire consists of the following domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry. Participants ranked their level of fatigue by using a 7-point scale from the worst response (1, high degree of fatigue) to the best response (7, minimal fatigue).

    Time frame: Baseline, 6 months (End Of Treatment)

  5. Mean Change From Baseline In Venous Ammonia Concentration At End Of Treatment

    Venous blood samples (10 mL) were collected at Baseline/Randomization (Day 0) and Days 28, 84, and 168. Baseline value was the last available value prior to first dose of study drug, and end of treatment value was the last available post-baseline value during the treatment period.

    Time frame: Baseline, Month 6 (End Of Treatment)

07

Results

Posted Aug 14, 2019

Participant flow

Participant flow — Overall Study
MilestoneRifaximinPlacebo
Started140159
Received at least 1 dose of study drug140159
Completed8866
Not completed5293
Withdrew: Lost to follow-up01
Withdrew: Liver transplant01
Withdrew: Protocol violation13
Withdrew: Death63
Withdrew: Withdrawal by subject69
Withdrew: Adverse event87
Withdrew: Breakthrough overt he episode2869
Withdrew: Noncompliance10
Withdrew: Cocaine abuse10
Withdrew: Severe gastrointestinal bleed10

Outcome measures

PrimaryTime To The First Breakthrough Overt HE Episode

Time to a breakthrough overt HE episode was the duration (number of days) from time of first dose of study drug to the first breakthrough overt HE episode. A breakthrough overt HE episode was defined as an increase of Conn score from Grade 0 or 1 to ≥2, or an increase in Conn and asterixis score of 1 grade each for those participants who entered the study with a Conn score of 0. Participants who completed the study and did not experience a breakthrough overt HE episode were censored at the time of their 6-month visit. Participants who terminated early for reasons other than a breakthrough overt HE episode were contacted at 6 months from randomization to determine if they had experienced a breakthrough overt HE event or other outcome. Participants without breakthrough overt HE were censored at the time of last contact or death, whichever was earlier. The number of events of a first breakthrough overt HE episode during the treatment interval is presented.

Time frame:
Baseline up to 6 Months (168 days)
Reported as:
Number · events
Time To The First Breakthrough Overt HE Episode
eventsRifaximinPlacebo
0 to <28 Days1320
28 to <56 Days423
56 to <84 Days614
84 to <140 Days710
140 to <168 Days16
≥168 Days00
Statistical analysis
  • Rifaximin vs Placebo · Cox proportional hazards model · p = <0.0001 · Hazard ratio (hr): 0.421 · 95% CI 0.276 to 0.641
SecondaryTime To First HE-related Hospitalization

Time to first HE-related hospitalization is defined as the duration (number of days) between the first dose of study drug and the date of first HE-related hospitalization. Participants who discontinued prior to hospitalization due to HE and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of participants with their first HE-related hospitalization per interval is presented. The number of events of the first HE-related hospitalization during the treatment interval is presented.

Time frame:
Baseline up to 6 months
Reported as:
Number · events
Time To First HE-related Hospitalization
eventsRifaximinPlacebo
0 to <28 Days411
28 to <56 Days412
56 to <84 Days47
84 to 140 Days54
140 to <168 Days22
≥168 Days00
SecondaryTime To Any Increase From Baseline In Conn Score

Time to any increase in Conn score (mental state grade) was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in Conn score. Conn score range: Grade 0 (no behavioral abnormality) to Grade 4 (coma; unable to test mental state). Participants who discontinued prior to experiencing an increase in Conn score and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in Conn score during the treatment interval is presented.

Time frame:
Baseline up to 6 months
Reported as:
Number · events
Time To Any Increase From Baseline In Conn Score
eventsRifaximinPlacebo
0 to <28 Days1726
28 to <56 Days521
56 to <84 Days915
84 to <140 Days510
140 to <168 Days05
≥168 Days10
SecondaryTime To Any Increase From Baseline In Asterixis Grade

Time to any increase in asterixis grade was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in asterixis grade. Asterixis (flapping tremor) was determined with the participant holding both arms and forearms extended with wrists dorsiflexed and fingers open for ≥30 seconds per standard practice. Asterixis grade range: Grade 0 (no abnormal movement) to Grade 4 (almost continuous flapping motions). Participants who discontinued prior to experiencing an increase in asterixis grade and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in asterixis grade during the treatment interval is presented.

Time frame:
Baseline up to 6 months
Reported as:
Number · events
Time To Any Increase From Baseline In Asterixis Grade
eventsRifaximinPlacebo
0 to <28 Days1320
28 to <56 Days715
56 to <84 Days74
84 to <140 Days36
140 to <168 Days14
≥168 Days11
SecondaryMean Change From Baseline In Fatigue Domain Score On The CLDQ At End Of Treatment

The 29-item Chronic Liver Disease Questionnaire (CLDQ) questionnaire consists of the following domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry. Participants ranked their level of fatigue by using a 7-point scale from the worst response (1, high degree of fatigue) to the best response (7, minimal fatigue).

Time frame:
Baseline, 6 months (End Of Treatment)
Reported as:
Mean · score on a scale
Mean Change From Baseline In Fatigue Domain Score On The CLDQ At End Of Treatment
score on a scaleRifaximinPlacebo
Baseline3.28 ± 1.3263.34 ± 1.406
Change from Baseline0.30 ± 1.2620.11 ± 1.319
SecondaryMean Change From Baseline In Venous Ammonia Concentration At End Of Treatment

Venous blood samples (10 mL) were collected at Baseline/Randomization (Day 0) and Days 28, 84, and 168. Baseline value was the last available value prior to first dose of study drug, and end of treatment value was the last available post-baseline value during the treatment period.

Time frame:
Baseline, Month 6 (End Of Treatment)
Reported as:
Mean · microgram per deciliter (ug/dL)
Mean Change From Baseline In Venous Ammonia Concentration At End Of Treatment
microgram per deciliter (ug/dL)RifaximinPlacebo
Baseline87.9 ± 47.7692.1 ± 55.24
Change from Baseline-5.7 ± 46.77-1.2 ± 60.98

Adverse events

Collected over Baseline up to 6.5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rifaximin—51/140 (36.4%)91/140 (65%)
Placebo—63/159 (39.6%)101/159 (63.5%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventRifaximinPlacebo
Hepatic encephalopathyNervous system disorders16/14034/159
Hepatic cirrhosisHepatobiliary disorders3/1406/159
AscitesGastrointestinal disorders4/1404/159
AnaemiaBlood and lymphatic system disorders4/1400/159
Oesophageal varices haemorrhageGastrointestinal disorders4/1402/159
PneumoniaInfections and infestations4/1401/159
Renal failure acuteRenal and urinary disorders2/1404/159
VomitingGastrointestinal disorders3/1400/159
Generalised oedemaGeneral disorders3/1402/159
CellulitisInfections and infestations3/1402/159
Most frequent other events
Showing 10 of 27
Most frequent other events
EventRifaximinPlacebo
Oedema peripheralGeneral disorders21/14013/159
NauseaGastrointestinal disorders19/14021/159
DiarrhoeaGastrointestinal disorders15/14021/159
DizzinessNervous system disorders18/14012/159
FatigueGeneral disorders17/14018/159
AscitesGastrointestinal disorders15/14013/159
HeadacheNervous system disorders14/14017/159
Hepatic encephalopathyNervous system disorders8/14016/159
Muscle spasmsMusculoskeletal and connective tissue disorders13/14011/159
PruritusSkin and subcutaneous tissue disorders13/14010/159

Baseline characteristics

Randomized participants who received at least 1 dose of study drug (ITT population).

Age, Continuous
Age, Continuous(years)RifaximinPlaceboTotal
Mean55.5 ± 9.5756.8 ± 9.1856.2 ± 56.0
Sex: Female, Male
Sex: Female, Male(Participants)RifaximinPlaceboTotal
Female6552117
Male75107182
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol. 2018 Sep 28;11:1756284818800307. doi: 10.1177/1756284818800307. eCollection 2018. PubMed 30283499 ↗
  • Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug 17. PubMed 21848797 ↗
  • Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893. PubMed 20335583 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2005 to primary completion in Aug 2008, 31 months.

Results were first posted in Aug 2019, 10 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2006
First posted
Mar 1, 2006
StartActual
Dec 19, 2005
Primary completionActual
Aug 15, 2008
CompletionActual
Aug 15, 2008
Results first posted
Aug 14, 2019
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00298038
Responsible party
Sponsor
First posted
Mar 1, 2006
Start date
Dec 19, 2005
Primary completion
Aug 15, 2008
Completion
Aug 15, 2008
Results posted
Aug 14, 2019
Last update
Sep 18, 2019

Study contacts

Lindsey Mathew
study director · Bausch Health Companies

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion